相关实验视频

Updated: Jan 15, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

在转移性结直肠癌中,基于牛利的化疗加上向性药物随着时间的推移改善了长期生存率:一项ARCAD数据库研究

Kazumasa Yamamoto¹, Hideaki Bando², Toshihiro Misumi³

¹Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.

European journal of cancer (Oxford, England : 1990)

|October 7, 2025

概括

转移性结直肠癌患者的存活率随着时间的推移逐渐改善,这些患者接受了oxaliplatin和向药物的治疗. 这凸显了基于生物标志物的策略和随后的治疗对患者生存的影响.

科学领域:

在瘤学瘤学.
临床试验临床试验
癌症研究癌症研究

背景情况:

转移性结直肠癌 (mCRC) 治疗标准包括基于氧沙的化疗与分子向药物相结合.
这种标准一线治疗的临床结果的时间趋势尚不清楚.
这项研究分析了接受这种治疗方案的mCRC患者的结果的时间变化.

研究的目的:

评估转移性结直肠癌患者临床结果的时间变化.
评估与一线基于氧沙的化疗加上分子向药物的生存趋势.
为了确定影响随着时间的推移生存改善的因素.

主要方法:

来自13个随机对照试验的5424名患者的个人患者数据元分析 (2004-2017年).
分析整体生存 (OS),无进展生存 (PFS) 和后进展生存 (PPS).
使用了卡普兰-梅尔和考克斯的比例危险模型,检查了治疗期 (2004-2008,2009-2013,2014-2017).

主要成果:

总体生存时间的中位数从21.4个月 (2004-2008) 提高到29.7个月 (2014-2017).
无进展和后进展生存率也显示了类似的上升趋势.
治疗时间是一个独立的预后因素;左侧和RAS野生型瘤的改善更为明显.

结论:

在mCRC患者中观察到生存结果的显著逐步改善,这些患者接受了第一线氧沙利platin加上向药物.
生物标志物驱动的治疗策略对于优化治疗结果至关重要.
随着后续疗法的不断变化的作用,有助于延长进展后的生存时间.

关键词:

帮助和研究癌症和消化道癌症.抗皮肤生长因子受体抗体.贝瓦西祖马布 (bevacizumab) 是一种药物.临床结果临床结果转移性结直肠癌是什么意思基于牛氧的双重化疗.

更多相关视频

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...